FIND is a product development partnership (PDP) — and the only one focused on diagnostics. As with all PDPs, partnerships are core to FIND’s business model. Partnerships enable FIND to address the challenges of research, development and use of diagnostic tests for poverty-related diseases, that meet the needs of both the public and private sectors in low- and middle-income countries.
Through partnerships, FIND acts as a bridge between the public and private sectors. This unique position brings a diverse set of stakeholders together to resolve technical, financial and logistical barriers to innovation in diagnostic tests for low-resource settings.
However, FIND does not focus only on product development. To ensure that co-developed products have the intended impact for national health programmes and people in even the most remote communities, FIND also supports implementation through laboratory strengthening and the roll-out of new diagnostic tools in endemic areas.
FIND currently has 185 active partnerships across numerous categories: 44 partnerships are with universities and research institutes; 46 with industry; 35 with governments or multilateral agencies; two with advocacy agencies (plus many more un-contracted, semi- or informal collaborations); 32 clinical trial sites; and 28 implementing partners.
Our partners include:
- Commercial companies, which have the technological know-how but may not have access to the financial incentives necessary to invest heavily in poverty-related diseases, including those with small markets, nor a deep understanding of the disease-causing agents;
- Academic and research institutions, often focused on basic research and conceptual innovation but ill-equipped for product development;
- International public health organizations and various NGOs and foundations, which play a major role in access to diagnostic products in endemic country markets
- Public donors or philanthropic organizations, which provide essential funding but are not implementers; and
- Health ministries and disease control programmes, which manage health-care systems in endemic countries (including the development and approval of national policies that guide the use of diagnostic tests, and the authorization of health commodities such as diagnostics and medicines) but do not develop the technologies.